174 patent applications, 267 intellectual properties, regulatory approval in 26 countries, recognition and certification from 81 companies, exports to 55 countries, FDA approval in the United States, certification from the Russian Federal Health Department (RZN).
Plasmapp (Youbong Lim, CEO) is a bio-device deep tech company that provides fast, affordable, and reliable infection management solutions. The advantage lies in approaching medical devices as a doctor with high-performance low-temperature plasma sterilization technology. It is a leading company in the medical market, thanks to the scalability and applicability of its exclusive technology-based convergence technology.
▲ Site Photo of Plasmapp's KOSDAQ Market Listing Approval Celebration (Photo provided by Plasmapp)
Plasmapp, which passed the KOSDAQ preliminary listing approval on August 11th, is scheduled to go public (IPO) in October, attracting the attention of investors.
It is essential for innovative technology companies with unique core technologies to protect their technology rights and expand the market through an IP strategy. The core system is built around technology professionals. As people who add technological value and embody the future vision, they are the capital.
We investigate the research and development of Bio Plasma by Plasmapp, which leads the bioindustry with innovative solutions that the market desires, and the capabilities of IP professionals.
▲ (From left) Director Hwang Gyu-ho, CEO Lim Youbong, Director Yeo Hyun-dong (Photo by Reporter Lee Geun-young)
Recently, Plasmapp recruited R&D-IP management experts, Director Yeo Hyun-dong and Manager Hwang Gyu-ho. Director Yeo Hyun-dong, an attorney-at-law, majored in chemistry and advanced materials engineering at KAIST. As a lawyer-engineer, he is an expert with a broad spectrum from technology to commercialization. He has been advising Plasmapp since its early founding and decided to join the company, trusting CEO Lim Youbong and sympathizing with the company's vision.
Director Yeo said, "Managing IP of a company that needs to sell good products at a low price should start with defining the scope of rights that create the market. From planning such as design and patents to research and development. It is planned to review the aspects of shape and functionality that are fragmented in the process of sequentially establishing rights. We will expand rights through patent applications that solidify the initial concept and consider shape and structure."
He further added, "Plasmapp's R&D professionals have played a crucial role in the company's value growth. We will enhance the intrinsic value of the company considering the IPO market and focus on internal control and management. I am proud to join as a colleague after the company has grown significantly and am eager to present the company's vision and work toward creating a company without discomfort."
"Breaking down the barriers of technology"
Manager Hwang Gyu-ho majored in mechanical engineering at Seoul National University, earned a Ph.D. in mechanical engineering from Carnegie Mellon University, and worked as a lawyer at Yong&YANG Hwang Woo.
Manager Hwang leads the legal rights protection of Plasmapp's bio-plasma core technology. He is devising a strategy considering the entire cycle from technology development to legal management after patent rights protection. The plan is to maintain the exclusive rights of core technology and fundamentally prevent any legal disputes that may arise between competing companies. The plan is to break down the barriers of technology to protect the monopoly technology.
As a mechanical engineer and a specialist in process equipment, Manager Hwang said, "We will clearly present the direction of trust-building, such as process management including product research and development and production. Legal issues and matters requiring internal alignment should also be considered. We will support IP lifecycle management that considers overseas patent applications in advance and focus on enhancing the reliability of technology and products for overseas market entry through overseas joint research."
He expressed, "I joined Plasmapp because I like the culture of startups that share common goals and share the growth, rewards, and profits of the company."
"A company where success becomes a habit, making everyone's meal"
Kim Jun-young, director of the Plasmapp Advanced Technology Research Institute, is a plasma expert who is more sincere about technology and products than anyone else. He is struggling for technological advancement and market expansion based on Plasmapp's flagship products, STERLINK (a pouch sterilization solution ten times faster and more economical) and ACTILINK (a vacuum plasma regeneration and activation solution 30 times cleaner, world's first).
Director Kim emphasized the implant surface treatment technology that integrates ACTILINK and STERLINK. It has the advantage of removing impurities remaining on the surface, expanding hydrophilicity, which removes the remaining impurities on the surface, increases cell and protein adhesion to the human body tissues more quickly.
Director Kim emphasized the advantages of Plasmapp, which simplified the sterilization process and made it compact, and paid attention to the possibility of expanding into the agricultural field. He focuses on research and development to increase seed sterilization and germination rate, performs plasma center and R&D tasks through sterilization records and data management, monitoring, and aims to play a role in new markets. He aims to expand research not only in bio-medical devices but also in engineering and natural sciences fields connected to plasma.
"Leading a development organization that excels in collaboration and communication"
Leading product development, Director Lee Jeong-hoon is an expert in materials and substances. He specializes in quality enhancement, modular design of components from the perspective of quality enhancement, and focuses on product implementation, approval, PV, PM, sales, and process enhancement.
Director Lee said, "Considering the applicability of bio-plasma in medical devices using plasma is the first time. It is a technology that realizes the formation of plasma and the polarization pattern of plasma within the product." He said.
He added, "In particular, we have proven the effect of enhancing germination by evolving seed treatment technology using bio-plasma technology, reflecting the requirements of skin irritation treatment products." He said, "We will focus on developing the mass production module of the seed treatment module in the future, focusing on proposing concepts and developing technology for large companies."
Products that meet the needs of the market and customers are those that satisfy reliable technology, quality, and design.
He emphasizes selection and focus. Focus on valuable tasks, reduce unnecessary tasks through process management, and make efforts for technological barrierization in the case of advanced technology. For intermediate technology, he seeks cooperation with partners possessing first-class technology, reduces development costs, and improves revenue models. He aims to lead a development organization that excels in collaboration and communication, leading Plasmapp to greater growth than ever before.
Meanwhile, Plasmapp held a KOSDAQ market listing approval celebration for its employees at InterContinental COEX Hotel on September 2nd and provided guidance on the subscription for the Employee Stock Ownership Association and internal transaction prevention education.
▲ Before the subscription for employee stock ownership association, Plasmapp CEO Lim Youbong presenting IR. (Photo by Reporter Lee Geun-young)
CEO Lim Youbong of Plasmapp said before the IR presentation for all employees, "The current growth is the result of your efforts so far. It will be an opportunity to share as shareholders beyond the company's members. I have confidently done numerous IRs, but it's the most nervous moment." He also reflected on his thoughts after the listing approval.
Source: FNTIMES (www.fntimes.com) |